Uproleselan

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs, particularly in oncology and inflammatory diseases. The company's lead candidate, uproleselan, is a first-in-class E-selectin antagonist designed to disrupt the interaction between leukemic cells and the bone marrow niche, potentially improving outcomes in acute myeloid leukemia (AML). GlycoMimetics utilizes a proprietary chemistry platform to design small molecules that mimic the structure and function of bioactive carbohydrates. Their pipeline also includes GMI-1687, a potent E-selectin antagonist for sickle cell disease, and other early-stage programs. The company is headquartered in Rockville, Maryland, and is publicly traded on the NASDAQ exchange.